• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Artificially sweetened beverages and health outcomes: an umbrella review
CONCLUSIONS: The consumption of ASBs was associated with a higher risk of obesity, type II diabetes, all-cause mortality, hypertension, and cardiovascular disease incidence. However, further cohort studies and clinical trials in humans are still needed to understand the impact of ASBs on health outcomes.PMID:37187453 | DOI:10.1016/j.advnut.2023.05.010
Source: Adv Data - May 15, 2023 Category: Epidemiology Authors: Cristina Diaz Leandro F M Rezende Angelo Sabag Dong Hoon Lee Gerson Ferrari Edward L Giovannucci Juan Pablo Rey-Lopez Source Type: research

Inflammation May Be the Culprit Behind Our Deadliest Diseases
In the early days of my medical residency, I met a man whom we’ll call Jason. He arrived to our emergency room on a holiday, nonchalant yet amiable, and complained of mild chest pain. Jason was tall and trim, with a strong South Boston accent and fingertips still faintly stained from his last home-improvement project. He was only 45 years old, but he looked much younger. He didn’t smoke, barely drank alcohol, and his cholesterol levels had always been normal. No one in his family had a history of heart disease. He asked us if we could work quickly—he wanted to be home for dinner with his daughters. [time-...
Source: TIME: Health - April 11, 2023 Category: Consumer Health News Authors: Shilpa Ravella Tags: Uncategorized freelance health Source Type: news

Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer
CONCLUSION: S-CSF2-Ab was useful for the diagnosis of atherosclerosis-related AIS, AMI, DM, and CKD and could discriminate poor prognosis, especially in p53-Ab-negative CRC.PMID:36844744 | PMC:PMC9954151 | DOI:10.3389/fcvm.2023.1042272
Source: Atherosclerosis - February 27, 2023 Category: Cardiology Authors: Shu-Yang Li Yoichi Yoshida Masaaki Kubota Bo-Shi Zhang Tomoo Matsutani Masaaki Ito Satoshi Yajima Kimihiko Yoshida Seiichiro Mine Toshio Machida Aiko Hayashi Minoru Takemoto Koutaro Yokote Mikiko Ohno Eiichiro Nishi Kenichiro Kitamura Ikuo Kamitsukasa Hir Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research

Pages: 1  2  3  4  5  6  7